trading halt

If the Chinese operations go under, there will be many Questions asked.....following was released months ago:

“Feedback from key opinion leaders in the treatment of HBV confirms our expectation of strong sales over the next 12 months exceeding RMB100 million ($A15.6 million) at high margin,” Mr Zhang added.
Mr Neil Leggett, outgoing Agenix CEO and Managing Director, who is in the process of relinquishing that role, commented: “The generation of initial sales in China is an important milestone in the corporate life of the Agenix which we started to transform 2 years ago. In China, we have established a growth platform which will be generating sales and profits, firstly in China and then elsewhere in Asia, as well as having a deep pipeline of other potential products in the anti-viral space. Our efforts have been recognized in a recent analyst valuation of Agenix at 36 cents per share, which we have made available on our website.”